Back

Halozyme Therapeutics Stock Predictions

Trump's "Document 20" Revealed: Smart Americans Could Get Rich During His 2nd Term

See if stocks could soar as much as 1,000% if history repeats itself.

Sell

HALO
Halozyme Therapeutics

Last Price:

45.65

Seasonality Move:

17.03%

7 Day Trial

ALL ACCESS PASS

$ 7

Trump's IRS Hands Massive 'Victory Gift' To 401K Owners

Shield your IRA, 401(k) and pension savings from this coming anti-Trump backlash.

Halozyme Therapeutics Stock Forecast

Over the next 52 weeks, Halozyme Therapeutics has on average historically risen by 32% based on the past 20 years of stock performance.
Halozyme Therapeutics has risen higher in 13 of those 20 years over the subsequent 52-week period, corresponding to a historical accuracy of 65%
Is Halozyme Therapeutics Stock Undervalued?
The current Halozyme Therapeutics [HALO] share price is $45.65. The Score for HALO is 39, which is 22% below its historic median score of 50, and infers higher risk than normal.
HALO is currently trading in the 30-40% percentile range relative to its historical Stock Score levels.

Will Halozyme Therapeutics Stock Go Up Next Year?

Over the next 52 weeks, Halozyme Therapeutics has on average historically risen by 32% based on the past 20 years of stock performance.

Halozyme Therapeutics Stock Rating

Sell

Halozyme Therapeutics (HALO) is a Sell

Is Halozyme Therapeutics overpriced?

Halozyme Therapeutics has risen higher in 13 of those 20 years over the subsequent 52-week period, corresponding to a historical accuracy of 65%

Halozyme Therapeutics Stock Price History

Is HALO stock going to rise?

Based on the share price being below its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bearish and HALO is experiencing selling pressure, which indicates risk of future bearish movement.

Stock Information

Stock Info

Exchange:

NASDAQ

Country:

United States

Industry:

Biotechnology

Sector:

Health Care

Type:

stock

Website:

halozyme.com

52-Week Data

52-Week High:

65.53

52-Week Low:

33.15

Prediction Charts

Market Cap:

5.81B

Price in USD:

45.65

Volume:

7.23M

Beta:

1.48

Technical Analysis

SMA50:

56.18

SMA100:

56.27

SMA200:

48.93

52-Wk Change:

16.04%

Stock Predictions

Is Halozyme Therapeutics stock public?
Yes, Halozyme Therapeutics is a publicly traded company.
What is the Halozyme Therapeutics stock quote today?
The Halozyme Therapeutics stock price is 45.65 USD today.
How to buy Halozyme Therapeutics stock online?
You can buy Halozyme Therapeutics shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.

14-Day Historical Data

Date	Opening	Closing	Minimum	Maximum
Oct-29	50.17	50.64	50.96	50.10
Oct-30	50.46	50.59	51.08	50.03
Oct-31	50.56	50.59	51.21	50.01
Nov-1	55.66	57.15	57.62	52.56
Nov-4	56.82	58.46	59.39	56.82
Nov-5	58.00	58.72	58.74	57.09
Nov-6	60.55	60.65	61.49	58.01
Nov-7	60.66	59.65	60.95	58.76
Nov-8	59.65	61.01	61.19	59.14
Nov-11	61.13	61.09	62.13	60.55
Nov-12	61.08	59.64	62.02	59.24
Nov-13	59.79	58.61	60.37	58.46
Nov-14	58.25	53.96	59.80	53.84
Nov-15	48.81	45.65	49.64	45.63

Halozyme Therapeutics Earnings

Halozyme Therapeutics Earnings Report: Per Share Halozyme Therapeutics Earnings Q1 Q2 Q3 and Q4 last year and next year.

Halozyme Therapeutics Forecast Revenue Growth

Halozyme Therapeutics Stock Analysis: Historical quarterly revenues per share for Halozyme Therapeutics and historical quarterly revenue growth:

Analysts estimate an earnings increase this quarter of $0.21 per share, a decrease next quarter of $0.00 per share, an increase this year of $1.30 per share, and an increase next year of $0.71 per share.

* Halozyme Therapeutics stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.